Patents Assigned to IRM LLC
  • Mechanically-Activated Cation Channels
    Publication number: 20130156762
    Abstract: Methods of screening for agents that modulate the activity of a mechanically-activated cation channel are provided. Also provided are compositions and methods for ameliorating pain by antagonizing or inhibiting mechanically-activated cation channels.
    Type: Application
    Filed: August 23, 2011
    Publication date: June 20, 2013
    Applicants: The Scripps Research Institute, IRM LLC
    Inventors: Bertrand Coste, Ardem Patapoutian
  • Compounds and compositions as TLR activity modulators
    Patent number: 8466167
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors, including TLR7 and TLR8. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine (formula I) wherein: X3 is N; X4 is N Or CR3; X5 is —CR4?CR5.
    Type: Grant
    Filed: February 27, 2009
    Date of Patent: June 18, 2013
    Assignees: IRM LLC, Novartis AG
    Inventors: Tom Yao Hsiang Wu, Yongkai Li, Alex Cortez, Yefen Zou, Pranab Mishra, Xiaoyue Zhang, David Skibinski, Manmohan Singh, Nicholas Valiante
  • DUAL FUNCTION PROTEINS FOR TREATING METABOLIC DISORDERS
    Publication number: 20130129724
    Abstract: The present invention relates to the identification of new proteins comprising fibroblast growth factor 21 (FGF21) and other metabolic regulators, including variants thereof, known to improve metabolic profiles in subjects to whom they are administered. Also disclosed are methods for treating FGF21-associated disorders, GLP-1-associated disorders, and Exendin-4-associated disorders, including metabolic conditions.
    Type: Application
    Filed: September 25, 2012
    Publication date: May 23, 2013
    Applicants: IRM LLC, NOVARTIS AG
    Inventors: Novartis AG, IRM LLC
  • Pyrimidine derivatives as kinase inhibitors
    Patent number: 8445505
    Abstract: The invention provides novel pyrimidine derivatives of formula (I) and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of insulin-like growth factor (IGF-IR) or analplastic lymphoma kinase (ALK).
    Type: Grant
    Filed: June 24, 2009
    Date of Patent: May 21, 2013
    Assignee: IRM LLC
    Inventors: Thomas H. Marsilje, III, Wenshuo Lu, Bei Chen, Xiaohui He, Songchun Jiang, Kunyong Yang
  • BENZONAPTHYRIDINE COMPOSITIONS AND USES THEREOF
    Publication number: 20130122042
    Abstract: The present invention generally relates to compositions comprising benzonapthyridine small molecule immune potentiators (SMIPs) that are capable of stimulating or modulating an immune response in a subject that has had pre- or post-exposure to a pathogen such as hemorrhagic fever virus. Also provided are methods of preparing and using the SMIP compositions of the invention.
    Type: Application
    Filed: April 13, 2011
    Publication date: May 16, 2013
    Applicants: Government of the United States, As Representing By the Secretary of the Army, IRM, LLC
    Inventors: Gillis Otten, Tom Yao-Hsiang Wu, Travis K. Warren, Sina Bavari
  • 2-biphenylamino-4-aminopyrimidine derivatives as kinase inhibitors
    Patent number: 8440681
    Abstract: The invention provides novel pyrimidine derivatives of formula (1) and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of insulin-like growth factor (IGF-1R) or anaplastic lymphoma kinase (ALK).
    Type: Grant
    Filed: August 27, 2008
    Date of Patent: May 14, 2013
    Assignee: IRM LLC
    Inventors: Thomas H. Marsilje, Wenshuo Lu, Bei Chen, Xiaohui He, Badry Bursulaya, Christian Cho-Hua Lee
  • Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
    Patent number: 8431607
    Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cannabinoid Receptor 1 (CB1).
    Type: Grant
    Filed: December 12, 2007
    Date of Patent: April 30, 2013
    Assignee: IRM LLC, A Delaware Limited Liability Company
    Inventors: Hong Liu, Xiaohui He, Dean Phillips, Xuefeng Zhu, Kunyong Yang, Thomas Lau, Baogen Wu, Yongping Xie, Truc Ngoc Nguyen, Xing Wang
  • COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS
    Publication number: 20130096165
    Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with or mediated by G protein-coupled receptors, in particular G protein-coupled receptor 120.
    Type: Application
    Filed: December 4, 2012
    Publication date: April 18, 2013
    Applicant: IRM LLC
    Inventor: IRM LLC
  • Compounds and compositions as protein kinase inhibitors
    Patent number: 8399450
    Abstract: The invention provides novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof.
    Type: Grant
    Filed: June 29, 2011
    Date of Patent: March 19, 2013
    Assignee: IRM LLC
    Inventors: Pierre-Yves Michellys, Wei Pei, Thomas H. Marsilje, Wenshuo Lu, Bei Chen, Tetsuo Uno, Yunho Jin, Tao Jiang
  • Compounds and methods for modulating G protein-coupled receptors
    Patent number: 8394841
    Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating G protein-coupled receptor 120 (GPR120), and methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated GPR120.
    Type: Grant
    Filed: January 8, 2008
    Date of Patent: March 12, 2013
    Assignee: IRM LLC
    Inventors: Robert Epple, Mihai Azimioara, Christopher Cow, Ross Russo, Victor Nikulin, Gerald Lelais
  • COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS
    Publication number: 20130059846
    Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit and PDGFR (PDGFR?, PDGFR?) kinases.
    Type: Application
    Filed: August 27, 2012
    Publication date: March 7, 2013
    Applicant: IRM LLC
    Inventors: Vince YEH, Xiaolin LI, Xiaodong LIU, Jon LOREN, Valentina MOLTENI, Juliet NABAKKA, Bao NGUYEN, Hank Michael James PETRASSI
  • Compounds and compositions as protein kinase inhibitors
    Patent number: 8377921
    Abstract: The invention provides novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof.
    Type: Grant
    Filed: June 29, 2011
    Date of Patent: February 19, 2013
    Assignee: IRM LLC
    Inventors: Pierre-Yves Michellys, Wei Pei, Thomas H. Marsilje, Bei Chen, Tetsuo Uno
  • Compounds and compositions as protein kinase inhibitors
    Patent number: 8372858
    Abstract: The invention provides novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof.
    Type: Grant
    Filed: March 15, 2011
    Date of Patent: February 12, 2013
    Assignee: IRM LLC
    Inventors: Pierre-Yves Michellys, Wei Pei, Thomas H. Marsilje, Bei Chen, Tetsuo Uno, Yunho Jin, Tao Jiang
  • Compounds and methods for modulating G protein-coupled receptors
    Patent number: 8362050
    Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with or mediated by G protein-coupled receptors, in particular G protein-coupled receptor 120.
    Type: Grant
    Filed: June 23, 2009
    Date of Patent: January 29, 2013
    Assignee: IRM LLC
    Inventors: Xiaohui He, Xuefeng Zhu, Kunyong Yang, Robert Epple, Hong Liu
  • Pyrido [4, 3-D] pyrimidinone derivatives as kinase inhibitors
    Patent number: 8354526
    Abstract: The invention provides a class of compounds of Formula (I), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly Syk, ZAP70, KDR, FMS, FLT3, c-Kit, RET, TrkA, TrkB, TrkC, IGR-IR, AIk, c-FMS, or combinations thereof.
    Type: Grant
    Filed: January 27, 2009
    Date of Patent: January 15, 2013
    Assignee: IRM LLC
    Inventors: Qiang Ding, Yahua Liu, Xu Wu, Qihui Jin, Jianwei Che, S. Frank Yan
  • COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
    Publication number: 20130005748
    Abstract: The invention provides novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof.
    Type: Application
    Filed: September 11, 2012
    Publication date: January 3, 2013
    Applicant: IRM LLC
    Inventors: Pierre-Yves Michellys, Wei Pei, Thomas H. Marsilje, Wenshuo Lu, Bei Chen, Tetsuo Uno, Yunho Jin, Tao Jiang
  • Compounds and compositions as c-kit and PDGFR kinase inhibitors
    Patent number: 8338417
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of c-kit, PDGFR and PDGFR kinases.
    Type: Grant
    Filed: May 2, 2008
    Date of Patent: December 25, 2012
    Assignees: IRM LLC, Novartis AG
    Inventors: Xiaolin Li, Xiaodong Liu, Valentina Molteni, Donatella Chianelli, Jon Loren, Juliet Nabakka, Timothy Ramsey, Werner Breitenstein
  • Compounds and compositions as channel activating protease inhibitors
    Patent number: 8338469
    Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating channel activating proteases, and methods for, using such compounds to treat, ameliorate or prevent a condition associated with a channel activating protease, including but not limited to prostasin, PRSS22, TMPRSS11 (e.g., TMPRSS11B, TMPRSS11E), TMPRSS2, TMPRSS3, TMPRSS4 (MTSP-2), matriptase (MTSP-1), CAP2, CAP3, trypsin, cathepsin A, or neutrophil elastase.
    Type: Grant
    Filed: April 19, 2011
    Date of Patent: December 25, 2012
    Assignee: IRM LLC
    Inventors: David C. Tully, Amab K. Chatterjee, Agnes Vidal, Hank Michael James Petrassi, Zhiwei Wang, Badry Bursulaya, Glen Spraggon
  • 4-phenoxymethylpiperidines as modulators of GPR119 activity
    Patent number: 8334288
    Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent; diseases or disorders associated with the activity of GPR119.
    Type: Grant
    Filed: July 9, 2009
    Date of Patent: December 18, 2012
    Assignee: IRM LLC
    Inventors: Robert Epple, Gerald Lelais, Victor Nikulin, Lucas Westcott-Baker
  • 5-(4-(haloalkoxy)phenyl) pyrimidine-2-amine compounds and compositions as kinase inhibitors
    Patent number: 8293757
    Abstract: The invention provides compounds of formula (1) and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit, PDGFR?, PDGFR?, CSF1R, AbI, BCR-AbI, CSK, JNK1, JNK2, p38, p70S6K, TGF?, SRC, EGFR, trkB, FGFR3. Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2?, BRK, Fms, KDR, c-rapor b-raf kinases.
    Type: Grant
    Filed: August 19, 2008
    Date of Patent: October 23, 2012
    Assignee: IRM LLC
    Inventors: Valentina Molteni, Xiaolin Li, Xiaodong Liu, Donatella Chianelli, Juliet Nabakka, Jon Loren, Shuli You